{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:25:24Z","timestamp":1792009524802,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730018"],"award-info":[{"award-number":["81730018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JC0003"],"award-info":[{"award-number":["2021JC0003"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejim.2023.05.038","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T16:18:08Z","timestamp":1686845888000},"page":"114-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease"],"prefix":"10.1016","volume":"115","author":[{"given":"Kaiyue","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2023.05.038_bib0001","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"issue":"10159","key":"10.1016\/j.ejim.2023.05.038_bib0002","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.05.038_bib0003","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"issue":"9889","key":"10.1016\/j.ejim.2023.05.038_bib0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2023.05.038_bib0006","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2215\/CJN.11111016","article-title":"Diagnosis and management of type 2 diabetic kidney disease","volume":"12","author":"Doshi","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"13","key":"10.1016\/j.ejim.2023.05.038_bib0007","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.038_bib0008","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.038_bib0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.038_bib0011","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ejim.2023.05.038_bib0012","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.038_bib0013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1210\/jcem-19-3-289","article-title":"Effects of intravenous infusions of dl-aldosterone acetate on sodium and potassium excretion in man","volume":"19","author":"Ross","year":"1959","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.038_bib0014","doi-asserted-by":"crossref","first-page":"C243","DOI":"10.1152\/ajpcell.00328.2015","article-title":"An unexpected journey: conceptual evolution of mechanoregulated potassium transport in the distal nephron","volume":"310","author":"Carrisoza-Gaytan","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"10.1016\/j.ejim.2023.05.038_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.ejim.2023.05.038_bib0016","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1681\/ASN.2007101079","article-title":"The aggravating mechanisms of aldosterone on kidney fibrosis","volume":"19","author":"Remuzzi","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2023.05.038_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.038_bib0018","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.038_bib0019","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejim.2023.05.038_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2023.05.038_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study","volume":"8","author":"Friedrich","year":"2008","journal-title":"BMC Med Res Methodol"},{"issue":"24","key":"10.1016\/j.ejim.2023.05.038_bib0023","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejim.2023.05.038_bib0024","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.038_bib0025","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.038_bib0026","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"31","key":"10.1016\/j.ejim.2023.05.038_bib0027","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ejim.2023.05.038_bib0028","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ejim.2023.05.038_bib0029","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.038_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0031","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the block-ckd study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0032","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1038\/s41598-020-73638-4","article-title":"The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"10","author":"Minakuchi","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.038_bib0033","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000508670","article-title":"A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy","volume":"10","author":"El Mokadem","year":"2020","journal-title":"Cardiorenal Med"},{"issue":"12","key":"10.1016\/j.ejim.2023.05.038_bib0034","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.ejim.2023.05.038_bib0035","doi-asserted-by":"crossref","first-page":"e64549","DOI":"10.1371\/journal.pone.0064549","article-title":"Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4\u2013a randomized controlled study","volume":"8","author":"Boesby","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12882-022-02711-z","article-title":"Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.038_bib0037","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0038","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320313481485","article-title":"Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy","volume":"16","author":"Momeni","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.038_bib0039","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3892\/etm.2013.1335","article-title":"Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and\/or angiotensin II receptor blockers on chronic glomerular disease","volume":"6","author":"Wang","year":"2013","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.038_bib0040","first-page":"648","article-title":"Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial","volume":"4","author":"Ziaee","year":"2013","journal-title":"Caspian J Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.038_bib0041","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.038_bib0042","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","article-title":"Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease","volume":"31","author":"Guney","year":"2009","journal-title":"Ren Fail"},{"issue":"12","key":"10.1016\/j.ejim.2023.05.038_bib0043","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2023.05.038_bib0044","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2265.2010.03832.x","article-title":"The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease","volume":"73","author":"Hammer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.038_bib0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.038_bib0046","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"issue":"12","key":"10.1016\/j.ejim.2023.05.038_bib0047","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ejim.2023.05.038_bib0048","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2023.05.038_bib0049","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cvr\/cvy013","article-title":"IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis","volume":"114","author":"Chou","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.038_bib0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","article-title":"Aldosterone-induced fibrosis in the kidney: questions and controversies","volume":"58","author":"Brem","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.038_bib0051","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.038_bib0052","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ndt\/gfr495","article-title":"Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease","volume":"27","author":"Lian","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.038_bib0053","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.ejim.2023.05.038_bib0054","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.ejim.2023.05.038_bib0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.038_bib0056","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.mayocp.2020.03.035","article-title":"Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure","volume":"95","author":"Secora","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.038_bib0057","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ddr.21760","article-title":"Role of mineralocorticoid receptor antagonists in kidney diseases","volume":"82","author":"Patel","year":"2021","journal-title":"Drug Dev Res"},{"issue":"9","key":"10.1016\/j.ejim.2023.05.038_bib0058","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2215\/CJN.02890221","article-title":"Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): results in the Prespecified Subgroup with Diabetes","volume":"16","author":"Agarwal","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2023.05.038_bib0059","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.kint.2020.07.009","article-title":"Gastrointestinal potassium binding in hemodialysis","volume":"98","author":"Palmer","year":"2020","journal-title":"Kidney Int"},{"issue":"10208","key":"10.1016\/j.ejim.2023.05.038_bib0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.038_bib0061","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ehf2.12265","article-title":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:38:45Z","timestamp":1760607525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523001966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":61,"alternative-id":["S0953620523001966"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.05.038","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}